[ARS] ENANTA PHARMACEUTICALS INC SEC Filing

Filing Impact

(Low)

Filing Sentiment

(Neutral)

Form Type

ARS

Rhea-AI Filing Summary

Analyzing...

01/26/2026 - 04:12 PM

ARS - ENANTA PHARMACEUTICALS INC

ARS Filing - ENANTA PHARMACEUTICALS INC

This filing is available as a PDF document.

Filing Type: ARS

Company: ENANTA PHARMACEUTICALS INC (ENTA)

Acceptance Date: 2026-01-26T16:12:07.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

Enanta Pharmaceuticals Inc

NASDAQ:ENTA

ENTA Rankings

#3793 Ranked by Market Cap

N/A Ranked by Dividends

ENTA Latest News

Jan 8, 2026

Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook

Jan 5, 2026

Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 17, 2025

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025

Nov 4, 2025

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences

Oct 20, 2025

Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025

ENTA Latest SEC Filings

Jan 26, 2026

[DEF 14A] ENANTA PHARMACEUTICALS INC Definitive Proxy Statement

Jan 20, 2026

[SCHEDULE 13G/A] ENANTA PHARMACEUTICALS INC Amended Passive Investment Disclosure

Dec 3, 2025

[Form 4] ENANTA PHARMACEUTICALS INC Insider Trading Activity

Nov 26, 2025

[Form 4] ENANTA PHARMACEUTICALS INC Insider Trading Activity

Nov 26, 2025

[Form 4] ENANTA PHARMACEUTICALS INC Insider Trading Activity

ENTA Stock Data

Market Cap 372.90M

Float 27.52M

Insiders Ownership 6.63%

Institutions Ownership 86.53%

Short Percent 13.26%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City WATERTOWN